铂耐药复发卵巢上皮性癌的治疗

Treatment for recurrent platinum-resistant epithelial ovarian carcinoma

卵巢上皮性癌病死率高居妇科常见恶性肿瘤首位,铂耐药复发是棘手的临床问题。铂耐药复发卵巢癌患者非铂单药化疗有效率仅10%~20%。化疗联合抗血管药物、PARP抑制剂、免疫检查点抑制剂等在铂耐药复发卵巢癌领域开展了诸多研究,给我们带来了新的选择。但是仍存在总体有效率不高、缺乏预测疗效的有效标志物等问题。

The case fatality rate of epithelial ovarian cancer is the highest among gynecological malignancies.Platinum resistance is a key clinical problem difficult to deal with.The efficacy of non-platinum chemotherapy is only 10%-20%.There have been many clinical trials about chemotherapy combined with anti-vascular agents,PARP inhibitors or immunecheckpoint inhibitors in platinum-resistant recurrent ovarian cancer,which have brought us new choices.However,there are still some problems,such as the low overall response rate and the lack of effective markersfor efficacy prediction.